Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10652258 | 0.90 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2HMOX2 | |
| SCHEMBL10650023 | 0.84 | CYP19A1 (0.66) | CYP19A1CYP11B1CYP11B2HMOX2 | |
| SCHEMBL10648284 | 0.84 | CYP19A1 (0.74) | CYP19A1CYP11B1CYP11B2HMOX2IDO1 | |
| SCHEMBL11701649 | 0.81 | HMOX1 (0.64) | HMOX1CYP19A1CYP11B1CYP11B2IDO1 | |
| SCHEMBL10197408 | 0.79 | HMOX1 (0.91) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10816487 | 0.79 | HMOX1 (0.91) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11450792 | 0.79 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10647315 | 0.79 | CYP19A1 (0.58) | CYP19A1HMOX2 | |
| SCHEMBL6971977 | 0.77 | HMOX1 (0.63) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL27956564 | 0.77 | HMOX1 (0.59) | HMOX1CYP19A1CYP11B1CYP11B2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| CN-101099463-A | Agrochemical composition, use for agrochemical composition and using method | OXITENO SA IND & COM (BR) | 2008-01-09 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | claimed |
| CN-1441790-A | Enhanced propertied pharmaceuticals | ROHM & HAAS (US) | 2003-09-10 | — | — | CN | claimed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| CN-110461143-A | Seed treatment compositions | MONSANTO TECHNOLOGY LLC | 2019-11-15 | — | — | CN | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0276583-A1 | Imidazole derivatives, processes for their preparation and their fungicidal properties | Instituto de Investigacion Y Desarrollo Quimico Biologico S.A. (ES) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | HMOX1 901/4885CYP19A1 946/4885CYP11B1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.